The translations of changes and translations of current measures from 1st March are in progress

maps_ugcInformation about available vaccines



From the beginning of the pandemic, the greatest effort of all scientists from around the world is to develop a safe vaccine against new coronavirus. To ensure maximal safety, only EU approved vaccines are allowed for usage in the Czech Republic (more about the vaccine approval process can be found in Related Links).

A vaccine against Covid-19 is a drug protecting individual from the disease caused by the new coronavirus SARS-CoV-2 by inducing immune system reaction against the virus. In layman’s terms, vaccine learns the body where are the weaknesses of the virus and how to produce adequate immune system reaction so that your immune system could kill the virus before its reproduction in the body.

Two of the existing vaccines are registered in the EU so far. The first approved vaccine was developed by Pfizer/Biontech, the second one by Moderna (from 6th January 2021).

OVERVIEW OF EXISTING VACCINES:

Pfizer/BioNTech

Vaccine type: gene vaccine, mRNA (only in Czech), coated with lipid nanoparticles
Registered in EU: yes
Ordered number of doses: 4 million
Number of doses per person: 2
The recommended interval between the doses: 28 days

First doses of Pfizer/BioNTech vaccine arrived in the Czech Republic on 26th December 2020, 9 750 doses in total. These doses are intended for priority vaccination of medical workers caring for patients with Covid-19 and already hospitalized seniors.

Vaccines have been distributed to The Military University Hospital Prague, General University Hospital Prague and Na Bulovce Hospital. The second half of doses has been delivered to The University Hospital Brno and St. Anne’s University Hospital Brno.

AstraZeneca

Vaccine type: recombinant, vector-based (adenovirus ChAdOx1)
Registered in EU: yes, conditional vaccine registration by EMA from 29th January 2021
Ordered number of doses: 3 million
Number of doses per person: 2
The recommended interval between the doses: 3 months

Johnson & Johnson

Vaccine type: vector-based (adenovirus Ad26)
Registered in EU: no, start of continuous monitoring in December 2020
Ordered number of doses: 2 million
Number of doses per person: 1

Sanofi Pasteur

Vaccine type: recombinant, adjuvanted
Registered in EU: no, expected approval during 2021
Ordered number of doses: not known, negotiations in progress –contract type allowing binding order only after Completing of 2/3 of clinical assessments
Number of doses per person: 2

Moderna

Vaccine type: gene vaccine, mRNA, coated with lipid nanoparticles
Registered in EU: yes
Ordered number of doses: 1.9 million
Number of doses per person: 2
The recommended interval between the doses: 28 days

Novavax

Vaccine type: recombinant, adjuvanted
Registered in EU: no, expected approval during 2021
Ordered number of doses: not known if this vaccine will be ordered
Number of doses per person: 2

CureVac

Vaccine type: gene vaccine, mRNA, coated with lipid nanoparticles
Registered in EU: no, no expectation about date of approval
Ordered number of doses: 1 million
Number of doses per person: 2

Number of doses is not equal to the number of people vaccinated due to different number of doses per person (either 1 or 2). 10 million of doses in total has been pre-ordered through the EU mechanism for approximately 6.9 million of individuals. It is not known exactly how many contracts can be concluded.

Please take into account that negotiations are still in progress and stated information may change.


Frequent questions about this topic

How the ordering process looks like? Has the Czech Republic power to change the size of deliveries?
How has a Covid vaccine been developed so quickly?